Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALK | Q9UM73 | 7/20 | 0.54 |
| ▸ | BRD4 | O60885 | 3/20 | 0.49 |
| ▸ | EGFR | P00533 | 4/20 | 0.47 |
| ▸ | SYK | P43405 | 3/20 | 0.47 |
| ▸ | CTSC | P53634 | 1/20 | 0.44 |
| ▸ | JAK2 | O60674 | 1/20 | 0.43 |
| ▸ | JAK1 | P23458 | 1/20 | 0.43 |
| ▸ | JAK3 | P52333 | 1/20 | 0.43 |
| ▸ | IGF1R | P08069 | 1/20 | 0.43 |
| ▸ | TTK | P33981 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1606279 | 0.92 | ALK (0.49) | ALKBRD4EGFRCTSCJAK2 | |
| SCHEMBL1607226 | 0.90 | BRD4 (0.49) | ALKBRD4EGFRCTSCJAK2 | |
| SCHEMBL1896619 | 0.86 | BRD4 (0.60) | ALKBRD4JAK2JAK1JAK3 | |
| SCHEMBL1880046 | 0.85 | ALK (0.54) | ALKBRD4EGFRSYKCTSC | |
| SCHEMBL1607609 | 0.83 | BRD4 (0.60) | ALKBRD4EGFRJAK2 | |
| SCHEMBL1606964 | 0.83 | BRD4 (0.60) | ALKBRD4EGFRJAK2JAK1 | |
| SCHEMBL1606982 | 0.81 | BRD4 (0.69) | ALKBRD4 | |
| SCHEMBL1878922 | 0.78 | ALK (0.49) | ALKBRD4EGFRCTSCJAK2 | |
| SCHEMBL1884694 | 0.77 | BRD4 (0.49) | ALKBRD4CTSCJAK2JAK3 | |
| SCHEMBL1906357 | 0.73 | BRD4 (0.72) | BRD4JAK2JAK1JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8304422-B2 | Compositions and methods for inhibition of the JAK pathway | RIGEL PHARMACEUTICALS, INC. (US) | 2012-11-06 | — | — | US | claimed |
| US-7947698-B2 | Prevent trabsplant rejection; autoimmune diseases | RIGEL PHARMACEUTICALS, INC. (US) | 2011-05-24 | — | — | US | claimed |
| US-20110082146-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. (US) | 2011-04-07 | — | — | US | claimed |
| US-20080279867-A1 | Prevent trabsplant rejection; autoimmune diseases | RIGEL PHARMACEUTICALS, INC. | 2008-11-13 | — | — | US | claimed |
| WO-2008118822-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. (US) | 2008-10-02 | — | — | WO | claimed |
| US-8304422-B2 | Compositions and methods for inhibition of the JAK pathway | RIGEL PHARMACEUTICALS, INC. (US) | 2012-11-06 | — | — | US | disclosed |
| US-7947698-B2 | Prevent trabsplant rejection; autoimmune diseases | RIGEL PHARMACEUTICALS, INC. (US) | 2011-05-24 | — | — | US | disclosed |
| US-20110082146-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. (US) | 2011-04-07 | — | — | US | disclosed |
| US-20080279867-A1 | Prevent trabsplant rejection; autoimmune diseases | RIGEL PHARMACEUTICALS, INC. | 2008-11-13 | — | — | US | disclosed |
| WO-2008118822-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. (US) | 2008-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110082146-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | JAK3, JAK2, JAK1 | ALK 557/4885BRD4 538/4885EGFR 529/4885 |
| US-20080279867-A1 | Prevent trabsplant rejection; autoimmune diseases | JAK3, JAK1, JAK2 | ALK 707/4885BRD4 2500/4885EGFR 1733/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.